nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Lomustine—hematologic cancer	0.0996	0.189	CbGbCtD
Methylnaltrexone—CYP2D6—Idarubicin—hematologic cancer	0.0887	0.168	CbGbCtD
Methylnaltrexone—CYP2D6—Hydroxyurea—hematologic cancer	0.0755	0.143	CbGbCtD
Methylnaltrexone—CYP2D6—Bortezomib—hematologic cancer	0.0656	0.124	CbGbCtD
Methylnaltrexone—CYP2D6—Imatinib—hematologic cancer	0.0481	0.0912	CbGbCtD
Methylnaltrexone—CYP2D6—Nilotinib—hematologic cancer	0.0437	0.0829	CbGbCtD
Methylnaltrexone—CYP2D6—Vinorelbine—hematologic cancer	0.0433	0.0822	CbGbCtD
Methylnaltrexone—CYP2D6—Vinblastine—hematologic cancer	0.0267	0.0506	CbGbCtD
Methylnaltrexone—CYP2D6—Dexamethasone—hematologic cancer	0.0198	0.0375	CbGbCtD
Methylnaltrexone—CYP2D6—Doxorubicin—hematologic cancer	0.0164	0.0311	CbGbCtD
Methylnaltrexone—Naloxone—CREB1—hematologic cancer	0.00404	0.446	CrCbGaD
Methylnaltrexone—Naltrexone—UGT1A1—hematologic cancer	0.00196	0.216	CrCbGaD
Methylnaltrexone—Buprenorphine—ABCG2—hematologic cancer	0.000808	0.0891	CrCbGaD
Methylnaltrexone—Naloxone—ESR1—hematologic cancer	0.000786	0.0866	CrCbGaD
Methylnaltrexone—Pain—Bleomycin—hematologic cancer	0.000537	0.00147	CcSEcCtD
Methylnaltrexone—Oedema—Ifosfamide—hematologic cancer	0.000537	0.00147	CcSEcCtD
Methylnaltrexone—Nausea—Busulfan—hematologic cancer	0.000537	0.00147	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vinorelbine—hematologic cancer	0.000534	0.00146	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Alitretinoin—hematologic cancer	0.000533	0.00146	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cladribine—hematologic cancer	0.000531	0.00145	CcSEcCtD
Methylnaltrexone—Pain—Vinorelbine—hematologic cancer	0.000529	0.00145	CcSEcCtD
Methylnaltrexone—Skin disorder—Alitretinoin—hematologic cancer	0.000528	0.00145	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ifosfamide—hematologic cancer	0.000527	0.00144	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Alitretinoin—hematologic cancer	0.000525	0.00144	CcSEcCtD
Methylnaltrexone—Dizziness—Nilotinib—hematologic cancer	0.000525	0.00144	CcSEcCtD
Methylnaltrexone—Oedema—Vincristine—hematologic cancer	0.000524	0.00143	CcSEcCtD
Methylnaltrexone—Dizziness—Imatinib—hematologic cancer	0.000522	0.00143	CcSEcCtD
Methylnaltrexone—Skin disorder—Ifosfamide—hematologic cancer	0.000522	0.00143	CcSEcCtD
Methylnaltrexone—Nausea—Procarbazine—hematologic cancer	0.000521	0.00143	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Ifosfamide—hematologic cancer	0.000519	0.00142	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Bortezomib—hematologic cancer	0.000518	0.00142	CcSEcCtD
Methylnaltrexone—Vomiting—Chlorambucil—hematologic cancer	0.000516	0.00141	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—hematologic cancer	0.000515	0.00141	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vincristine—hematologic cancer	0.000514	0.00141	CcSEcCtD
Methylnaltrexone—Dizziness—Cladribine—hematologic cancer	0.000513	0.00141	CcSEcCtD
Methylnaltrexone—Erythema—Prednisolone—hematologic cancer	0.000513	0.0014	CcSEcCtD
Methylnaltrexone—Nausea—Bexarotene—hematologic cancer	0.000511	0.0014	CcSEcCtD
Methylnaltrexone—Nausea—Dasatinib—hematologic cancer	0.000511	0.0014	CcSEcCtD
Methylnaltrexone—Oedema—Mitoxantrone—hematologic cancer	0.00051	0.0014	CcSEcCtD
Methylnaltrexone—Oedema—Irinotecan—hematologic cancer	0.00051	0.0014	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Thiotepa—hematologic cancer	0.00051	0.0014	CcSEcCtD
Methylnaltrexone—Nausea—Fludarabine—hematologic cancer	0.000509	0.00139	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinblastine—hematologic cancer	0.000509	0.00139	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Vincristine—hematologic cancer	0.000506	0.00139	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vinorelbine—hematologic cancer	0.000506	0.00138	CcSEcCtD
Methylnaltrexone—Pain—Thiotepa—hematologic cancer	0.000505	0.00138	CcSEcCtD
Methylnaltrexone—Vomiting—Nilotinib—hematologic cancer	0.000505	0.00138	CcSEcCtD
Methylnaltrexone—Vomiting—Imatinib—hematologic cancer	0.000502	0.00138	CcSEcCtD
Methylnaltrexone—Abdominal pain—Bortezomib—hematologic cancer	0.000501	0.00137	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Irinotecan—hematologic cancer	0.0005	0.00137	CcSEcCtD
Methylnaltrexone—Oedema—Gemcitabine—hematologic cancer	0.000497	0.00136	CcSEcCtD
Methylnaltrexone—Skin disorder—Mitoxantrone—hematologic cancer	0.000495	0.00136	CcSEcCtD
Methylnaltrexone—Vomiting—Cladribine—hematologic cancer	0.000493	0.00135	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Thalidomide—hematologic cancer	0.000493	0.00135	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Irinotecan—hematologic cancer	0.000493	0.00135	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mitoxantrone—hematologic cancer	0.000493	0.00135	CcSEcCtD
Methylnaltrexone—Dizziness—Vinblastine—hematologic cancer	0.000492	0.00135	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vinorelbine—hematologic cancer	0.000489	0.00134	CcSEcCtD
Methylnaltrexone—Pain—Thalidomide—hematologic cancer	0.000488	0.00134	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gemcitabine—hematologic cancer	0.000487	0.00133	CcSEcCtD
Methylnaltrexone—Diarrhoea—Melphalan—hematologic cancer	0.000484	0.00133	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Thiotepa—hematologic cancer	0.000483	0.00132	CcSEcCtD
Methylnaltrexone—Skin disorder—Gemcitabine—hematologic cancer	0.000483	0.00132	CcSEcCtD
Methylnaltrexone—Nausea—Chlorambucil—hematologic cancer	0.000482	0.00132	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gemcitabine—hematologic cancer	0.00048	0.00132	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—hematologic cancer	0.00048	0.00131	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Carmustine—hematologic cancer	0.000474	0.0013	CcSEcCtD
Methylnaltrexone—Vomiting—Vinblastine—hematologic cancer	0.000473	0.0013	CcSEcCtD
Methylnaltrexone—Nausea—Nilotinib—hematologic cancer	0.000472	0.00129	CcSEcCtD
Methylnaltrexone—Erythema—Triamcinolone—hematologic cancer	0.000471	0.00129	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lenalidomide—hematologic cancer	0.000471	0.00129	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.000469	0.00128	CcSEcCtD
Methylnaltrexone—Pain—Carmustine—hematologic cancer	0.000469	0.00128	CcSEcCtD
Methylnaltrexone—Nausea—Imatinib—hematologic cancer	0.000469	0.00128	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Thalidomide—hematologic cancer	0.000467	0.00128	CcSEcCtD
Methylnaltrexone—Abdominal pain—Thiotepa—hematologic cancer	0.000467	0.00128	CcSEcCtD
Methylnaltrexone—Pain—Alitretinoin—hematologic cancer	0.000465	0.00127	CcSEcCtD
Methylnaltrexone—Diarrhoea—Hydroxyurea—hematologic cancer	0.000464	0.00127	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000464	0.00127	CcSEcCtD
Methylnaltrexone—Oedema—Cisplatin—hematologic cancer	0.000463	0.00127	CcSEcCtD
Methylnaltrexone—Nausea—Cladribine—hematologic cancer	0.000461	0.00126	CcSEcCtD
Methylnaltrexone—Pain—Ifosfamide—hematologic cancer	0.000459	0.00126	CcSEcCtD
Methylnaltrexone—Naltrexone—ABCB1—hematologic cancer	0.000458	0.0505	CrCbGaD
Methylnaltrexone—Dizziness—Lenalidomide—hematologic cancer	0.000455	0.00125	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cisplatin—hematologic cancer	0.000454	0.00124	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000452	0.00124	CcSEcCtD
Methylnaltrexone—Abdominal pain—Thalidomide—hematologic cancer	0.000452	0.00124	CcSEcCtD
Methylnaltrexone—Vomiting—Melphalan—hematologic cancer	0.00045	0.00123	CcSEcCtD
Methylnaltrexone—Skin disorder—Cisplatin—hematologic cancer	0.00045	0.00123	CcSEcCtD
Methylnaltrexone—Dizziness—Hydroxyurea—hematologic cancer	0.000449	0.00123	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Carmustine—hematologic cancer	0.000449	0.00123	CcSEcCtD
Methylnaltrexone—Pain—Vincristine—hematologic cancer	0.000448	0.00123	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Cisplatin—hematologic cancer	0.000448	0.00123	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Alitretinoin—hematologic cancer	0.000444	0.00122	CcSEcCtD
Methylnaltrexone—Nausea—Vinblastine—hematologic cancer	0.000442	0.00121	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.00044	0.00121	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—hematologic cancer	0.000439	0.0012	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ifosfamide—hematologic cancer	0.000439	0.0012	CcSEcCtD
Methylnaltrexone—Vomiting—Lenalidomide—hematologic cancer	0.000438	0.0012	CcSEcCtD
Methylnaltrexone—Pain—Mitoxantrone—hematologic cancer	0.000436	0.00119	CcSEcCtD
Methylnaltrexone—Pain—Irinotecan—hematologic cancer	0.000436	0.00119	CcSEcCtD
Methylnaltrexone—Abdominal pain—Carmustine—hematologic cancer	0.000434	0.00119	CcSEcCtD
Methylnaltrexone—Diarrhoea—Bortezomib—hematologic cancer	0.000433	0.00119	CcSEcCtD
Methylnaltrexone—Vomiting—Hydroxyurea—hematologic cancer	0.000431	0.00118	CcSEcCtD
Methylnaltrexone—Abdominal pain—Alitretinoin—hematologic cancer	0.00043	0.00118	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000429	0.00117	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vincristine—hematologic cancer	0.000428	0.00117	CcSEcCtD
Methylnaltrexone—Erythema—Betamethasone—hematologic cancer	0.000428	0.00117	CcSEcCtD
Methylnaltrexone—Erythema—Dexamethasone—hematologic cancer	0.000428	0.00117	CcSEcCtD
Methylnaltrexone—Pain—Gemcitabine—hematologic cancer	0.000425	0.00116	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ifosfamide—hematologic cancer	0.000425	0.00116	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinorelbine—hematologic cancer	0.000423	0.00116	CcSEcCtD
Methylnaltrexone—Nausea—Melphalan—hematologic cancer	0.00042	0.00115	CcSEcCtD
Methylnaltrexone—Dizziness—Bortezomib—hematologic cancer	0.000419	0.00115	CcSEcCtD
Methylnaltrexone—Oedema—Prednisolone—hematologic cancer	0.000418	0.00115	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mitoxantrone—hematologic cancer	0.000417	0.00114	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Irinotecan—hematologic cancer	0.000417	0.00114	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vincristine—hematologic cancer	0.000414	0.00113	CcSEcCtD
Methylnaltrexone—Skin disorder—Etoposide—hematologic cancer	0.000412	0.00113	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Etoposide—hematologic cancer	0.00041	0.00112	CcSEcCtD
Methylnaltrexone—Dizziness—Vinorelbine—hematologic cancer	0.000409	0.00112	CcSEcCtD
Methylnaltrexone—Nausea—Lenalidomide—hematologic cancer	0.000409	0.00112	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisolone—hematologic cancer	0.000404	0.00111	CcSEcCtD
Methylnaltrexone—Diarrhoea—Thiotepa—hematologic cancer	0.000404	0.00111	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mitoxantrone—hematologic cancer	0.000403	0.0011	CcSEcCtD
Methylnaltrexone—Abdominal pain—Irinotecan—hematologic cancer	0.000403	0.0011	CcSEcCtD
Methylnaltrexone—Nausea—Hydroxyurea—hematologic cancer	0.000403	0.0011	CcSEcCtD
Methylnaltrexone—Vomiting—Bortezomib—hematologic cancer	0.000403	0.0011	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.0004	0.00109	CcSEcCtD
Methylnaltrexone—Vomiting—Bleomycin—hematologic cancer	0.0004	0.00109	CcSEcCtD
Methylnaltrexone—Pain—Cisplatin—hematologic cancer	0.000396	0.00108	CcSEcCtD
Methylnaltrexone—Vomiting—Vinorelbine—hematologic cancer	0.000393	0.00108	CcSEcCtD
Methylnaltrexone—Diarrhoea—Thalidomide—hematologic cancer	0.000391	0.00107	CcSEcCtD
Methylnaltrexone—Dizziness—Thiotepa—hematologic cancer	0.000391	0.00107	CcSEcCtD
Methylnaltrexone—Oedema—Triamcinolone—hematologic cancer	0.000385	0.00105	CcSEcCtD
Methylnaltrexone—Dizziness—Thalidomide—hematologic cancer	0.000378	0.00103	CcSEcCtD
Methylnaltrexone—Nausea—Bortezomib—hematologic cancer	0.000376	0.00103	CcSEcCtD
Methylnaltrexone—Vomiting—Thiotepa—hematologic cancer	0.000375	0.00103	CcSEcCtD
Methylnaltrexone—Diarrhoea—Carmustine—hematologic cancer	0.000375	0.00103	CcSEcCtD
Methylnaltrexone—Nausea—Bleomycin—hematologic cancer	0.000373	0.00102	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—hematologic cancer	0.000373	0.00102	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Triamcinolone—hematologic cancer	0.000372	0.00102	CcSEcCtD
Methylnaltrexone—Diarrhoea—Alitretinoin—hematologic cancer	0.000372	0.00102	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ifosfamide—hematologic cancer	0.000368	0.00101	CcSEcCtD
Methylnaltrexone—Nausea—Vinorelbine—hematologic cancer	0.000367	0.00101	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000366	0.001	CcSEcCtD
Methylnaltrexone—Vomiting—Thalidomide—hematologic cancer	0.000363	0.000995	CcSEcCtD
Methylnaltrexone—Dizziness—Carmustine—hematologic cancer	0.000363	0.000994	CcSEcCtD
Methylnaltrexone—Pain—Etoposide—hematologic cancer	0.000363	0.000994	CcSEcCtD
Methylnaltrexone—Dizziness—Alitretinoin—hematologic cancer	0.000359	0.000984	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vincristine—hematologic cancer	0.000358	0.000981	CcSEcCtD
Methylnaltrexone—Pain—Prednisolone—hematologic cancer	0.000358	0.00098	CcSEcCtD
Methylnaltrexone—Dizziness—Ifosfamide—hematologic cancer	0.000355	0.000973	CcSEcCtD
Methylnaltrexone—Nausea—Thiotepa—hematologic cancer	0.000351	0.000961	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—hematologic cancer	0.00035	0.0386	CrCbGaD
Methylnaltrexone—Oedema—Betamethasone—hematologic cancer	0.000349	0.000956	CcSEcCtD
Methylnaltrexone—Oedema—Dexamethasone—hematologic cancer	0.000349	0.000956	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mitoxantrone—hematologic cancer	0.000349	0.000956	CcSEcCtD
Methylnaltrexone—Diarrhoea—Irinotecan—hematologic cancer	0.000349	0.000956	CcSEcCtD
Methylnaltrexone—Vomiting—Carmustine—hematologic cancer	0.000349	0.000955	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etoposide—hematologic cancer	0.000347	0.00095	CcSEcCtD
Methylnaltrexone—Dizziness—Vincristine—hematologic cancer	0.000346	0.000948	CcSEcCtD
Methylnaltrexone—Vomiting—Alitretinoin—hematologic cancer	0.000346	0.000946	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Dexamethasone—hematologic cancer	0.000342	0.000938	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Betamethasone—hematologic cancer	0.000342	0.000938	CcSEcCtD
Methylnaltrexone—Vomiting—Ifosfamide—hematologic cancer	0.000342	0.000935	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gemcitabine—hematologic cancer	0.00034	0.000931	CcSEcCtD
Methylnaltrexone—Nausea—Thalidomide—hematologic cancer	0.000339	0.000929	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Betamethasone—hematologic cancer	0.000338	0.000924	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Dexamethasone—hematologic cancer	0.000338	0.000924	CcSEcCtD
Methylnaltrexone—Dizziness—Irinotecan—hematologic cancer	0.000337	0.000924	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCB1—hematologic cancer	0.000336	0.0371	CrCbGaD
Methylnaltrexone—Abdominal pain—Etoposide—hematologic cancer	0.000335	0.000918	CcSEcCtD
Methylnaltrexone—Naloxone—ABCB1—hematologic cancer	0.000334	0.0368	CrCbGaD
Methylnaltrexone—Vomiting—Vincristine—hematologic cancer	0.000333	0.000912	CcSEcCtD
Methylnaltrexone—Pain—Triamcinolone—hematologic cancer	0.000329	0.000901	CcSEcCtD
Methylnaltrexone—Nausea—Carmustine—hematologic cancer	0.000326	0.000892	CcSEcCtD
Methylnaltrexone—Vomiting—Mitoxantrone—hematologic cancer	0.000324	0.000888	CcSEcCtD
Methylnaltrexone—Vomiting—Irinotecan—hematologic cancer	0.000324	0.000888	CcSEcCtD
Methylnaltrexone—Nausea—Alitretinoin—hematologic cancer	0.000323	0.000884	CcSEcCtD
Methylnaltrexone—Nausea—Ifosfamide—hematologic cancer	0.000319	0.000874	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cisplatin—hematologic cancer	0.000317	0.000868	CcSEcCtD
Methylnaltrexone—Vomiting—Gemcitabine—hematologic cancer	0.000316	0.000865	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.000315	0.000863	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—hematologic cancer	0.000311	0.000853	CcSEcCtD
Methylnaltrexone—Nausea—Vincristine—hematologic cancer	0.000311	0.000852	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—hematologic cancer	0.000304	0.000833	CcSEcCtD
Methylnaltrexone—Nausea—Mitoxantrone—hematologic cancer	0.000303	0.00083	CcSEcCtD
Methylnaltrexone—Nausea—Irinotecan—hematologic cancer	0.000303	0.00083	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000301	0.000825	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000301	0.000825	CcSEcCtD
Methylnaltrexone—Pain—Betamethasone—hematologic cancer	0.000299	0.000818	CcSEcCtD
Methylnaltrexone—Pain—Dexamethasone—hematologic cancer	0.000299	0.000818	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—hematologic cancer	0.000298	0.000817	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—hematologic cancer	0.000295	0.000809	CcSEcCtD
Methylnaltrexone—Nausea—Gemcitabine—hematologic cancer	0.000295	0.000808	CcSEcCtD
Methylnaltrexone—Vomiting—Cisplatin—hematologic cancer	0.000294	0.000806	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisone—hematologic cancer	0.000294	0.000805	CcSEcCtD
Methylnaltrexone—Erythema—Epirubicin—hematologic cancer	0.000291	0.000798	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etoposide—hematologic cancer	0.00029	0.000795	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—hematologic cancer	0.000287	0.000786	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Betamethasone—hematologic cancer	0.000285	0.000782	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.000285	0.000782	CcSEcCtD
Methylnaltrexone—Dizziness—Etoposide—hematologic cancer	0.000281	0.000768	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisolone—hematologic cancer	0.000277	0.000758	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dexamethasone—hematologic cancer	0.000276	0.000756	CcSEcCtD
Methylnaltrexone—Abdominal pain—Betamethasone—hematologic cancer	0.000276	0.000756	CcSEcCtD
Methylnaltrexone—Nausea—Cisplatin—hematologic cancer	0.000275	0.000753	CcSEcCtD
Methylnaltrexone—Vomiting—Etoposide—hematologic cancer	0.00027	0.000739	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—hematologic cancer	0.00027	0.000738	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—hematologic cancer	0.000266	0.000728	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	0.000263	0.000721	CcSEcCtD
Methylnaltrexone—Dizziness—Triamcinolone—hematologic cancer	0.000254	0.000697	CcSEcCtD
Methylnaltrexone—Nausea—Etoposide—hematologic cancer	0.000252	0.00069	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methotrexate—hematologic cancer	0.000249	0.000682	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—hematologic cancer	0.000249	0.000681	CcSEcCtD
Methylnaltrexone—Nausea—Prednisolone—hematologic cancer	0.000249	0.000681	CcSEcCtD
Methylnaltrexone—Skin disorder—Methotrexate—hematologic cancer	0.000247	0.000676	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	0.000246	0.000675	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methotrexate—hematologic cancer	0.000246	0.000673	CcSEcCtD
Methylnaltrexone—Vomiting—Triamcinolone—hematologic cancer	0.000245	0.00067	CcSEcCtD
Methylnaltrexone—Abdominal pain—Prednisone—hematologic cancer	0.00024	0.000658	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dexamethasone—hematologic cancer	0.000239	0.000654	CcSEcCtD
Methylnaltrexone—Diarrhoea—Betamethasone—hematologic cancer	0.000239	0.000654	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—hematologic cancer	0.000238	0.000651	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—hematologic cancer	0.000233	0.000639	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—hematologic cancer	0.000231	0.000633	CcSEcCtD
Methylnaltrexone—Dizziness—Betamethasone—hematologic cancer	0.000231	0.000632	CcSEcCtD
Methylnaltrexone—Dizziness—Dexamethasone—hematologic cancer	0.000231	0.000632	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—hematologic cancer	0.00023	0.00063	CcSEcCtD
Methylnaltrexone—Nausea—Triamcinolone—hematologic cancer	0.000229	0.000626	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	0.000228	0.000624	CcSEcCtD
Methylnaltrexone—Vomiting—Betamethasone—hematologic cancer	0.000222	0.000608	CcSEcCtD
Methylnaltrexone—Vomiting—Dexamethasone—hematologic cancer	0.000222	0.000608	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—hematologic cancer	0.00022	0.000603	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000219	0.000601	CcSEcCtD
Methylnaltrexone—Pain—Methotrexate—hematologic cancer	0.000217	0.000595	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—hematologic cancer	0.000216	0.000591	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—hematologic cancer	0.000214	0.000585	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—hematologic cancer	0.000213	0.000583	CcSEcCtD
Methylnaltrexone—Diarrhoea—Prednisone—hematologic cancer	0.000208	0.00057	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—hematologic cancer	0.000208	0.000569	CcSEcCtD
Methylnaltrexone—Nausea—Betamethasone—hematologic cancer	0.000207	0.000568	CcSEcCtD
Methylnaltrexone—Nausea—Dexamethasone—hematologic cancer	0.000207	0.000568	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000205	0.000562	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—hematologic cancer	0.000203	0.000557	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisone—hematologic cancer	0.000201	0.000551	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—hematologic cancer	0.000201	0.00055	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—hematologic cancer	0.000194	0.000533	CcSEcCtD
Methylnaltrexone—Vomiting—Prednisone—hematologic cancer	0.000193	0.000529	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.00019	0.00052	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—hematologic cancer	0.000188	0.000515	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—hematologic cancer	0.000188	0.000515	CcSEcCtD
Methylnaltrexone—Nausea—Prednisone—hematologic cancer	0.000181	0.000495	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—hematologic cancer	0.00018	0.000493	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—hematologic cancer	0.000174	0.000476	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methotrexate—hematologic cancer	0.000174	0.000476	CcSEcCtD
Methylnaltrexone—Dizziness—Methotrexate—hematologic cancer	0.000168	0.00046	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—hematologic cancer	0.000163	0.000446	CcSEcCtD
Methylnaltrexone—Vomiting—Methotrexate—hematologic cancer	0.000162	0.000442	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—hematologic cancer	0.000157	0.000431	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—hematologic cancer	0.000151	0.000414	CcSEcCtD
Methylnaltrexone—Nausea—Methotrexate—hematologic cancer	0.000151	0.000413	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—hematologic cancer	0.000151	0.000412	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—hematologic cancer	0.000145	0.000398	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—hematologic cancer	0.000141	0.000387	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—hematologic cancer	0.00014	0.000383	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—hematologic cancer	0.000131	0.000358	CcSEcCtD
Methylnaltrexone—OPRK1—Signaling Pathways—CBL—hematologic cancer	3.72e-05	0.000379	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTAP—hematologic cancer	3.72e-05	0.000378	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2RA—hematologic cancer	3.69e-05	0.000376	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL3—hematologic cancer	3.68e-05	0.000375	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTGER4—hematologic cancer	3.65e-05	0.000372	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—hematologic cancer	3.64e-05	0.00037	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LCK—hematologic cancer	3.63e-05	0.00037	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTPN1—hematologic cancer	3.62e-05	0.000368	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTPN11—hematologic cancer	3.57e-05	0.000364	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—H3F3A—hematologic cancer	3.56e-05	0.000363	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RASGRP1—hematologic cancer	3.56e-05	0.000362	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HSP90AA1—hematologic cancer	3.55e-05	0.000361	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SYK—hematologic cancer	3.55e-05	0.000361	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—hematologic cancer	3.52e-05	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCZ—hematologic cancer	3.46e-05	0.000353	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CREB1—hematologic cancer	3.46e-05	0.000352	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT1—hematologic cancer	3.42e-05	0.000348	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—hematologic cancer	3.39e-05	0.000345	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—hematologic cancer	3.38e-05	0.000345	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6R—hematologic cancer	3.38e-05	0.000344	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PARP1—hematologic cancer	3.34e-05	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3R1—hematologic cancer	3.32e-05	0.000338	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FHL2—hematologic cancer	3.31e-05	0.000337	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FBXW7—hematologic cancer	3.29e-05	0.000335	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGRN—hematologic cancer	3.25e-05	0.000331	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—JAK2—hematologic cancer	3.23e-05	0.000329	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR4—hematologic cancer	3.23e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HDAC2—hematologic cancer	3.23e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAP2K1—hematologic cancer	3.22e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GRB2—hematologic cancer	3.2e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—hematologic cancer	3.2e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFA—hematologic cancer	3.19e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KITLG—hematologic cancer	3.15e-05	0.000321	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CBL—hematologic cancer	3.14e-05	0.00032	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL3—hematologic cancer	3.11e-05	0.000317	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMMR—hematologic cancer	3.08e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—IDH2—hematologic cancer	3.08e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT5A—hematologic cancer	3.08e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—hematologic cancer	3.07e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—hematologic cancer	3.07e-05	0.000312	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTPN1—hematologic cancer	3.06e-05	0.000311	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN2B—hematologic cancer	3.05e-05	0.000311	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTPN11—hematologic cancer	3.02e-05	0.000307	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3R1—hematologic cancer	3.02e-05	0.000307	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RASGRP1—hematologic cancer	3.01e-05	0.000306	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HSP90AA1—hematologic cancer	3e-05	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SYK—hematologic cancer	3e-05	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.98e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD86—hematologic cancer	2.95e-05	0.0003	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—JAK2—hematologic cancer	2.93e-05	0.000299	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CREB1—hematologic cancer	2.93e-05	0.000298	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HES1—hematologic cancer	2.91e-05	0.000296	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ARNTL—hematologic cancer	2.89e-05	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NCOR1—hematologic cancer	2.89e-05	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT1—hematologic cancer	2.89e-05	0.000294	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—hematologic cancer	2.86e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CSF2—hematologic cancer	2.86e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF1—hematologic cancer	2.86e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6R—hematologic cancer	2.85e-05	0.000291	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FOXO1—hematologic cancer	2.82e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—hematologic cancer	2.82e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACP5—hematologic cancer	2.82e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CA9—hematologic cancer	2.82e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFRB—hematologic cancer	2.81e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.81e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—hematologic cancer	2.79e-05	0.000284	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOR2—hematologic cancer	2.78e-05	0.000283	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFRA—hematologic cancer	2.77e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCG—hematologic cancer	2.76e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAK1—hematologic cancer	2.76e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—JAK2—hematologic cancer	2.73e-05	0.000278	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAP2K1—hematologic cancer	2.72e-05	0.000277	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRB2—hematologic cancer	2.71e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—hematologic cancer	2.7e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFA—hematologic cancer	2.7e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KITLG—hematologic cancer	2.66e-05	0.000271	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—IDH1—hematologic cancer	2.65e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCC3—hematologic cancer	2.62e-05	0.000266	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TXN—hematologic cancer	2.62e-05	0.000266	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTO1—hematologic cancer	2.62e-05	0.000266	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT5A—hematologic cancer	2.6e-05	0.000265	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—hematologic cancer	2.59e-05	0.000264	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2RA—hematologic cancer	2.58e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN2B—hematologic cancer	2.58e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SPHK1—hematologic cancer	2.56e-05	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—hematologic cancer	2.56e-05	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3R1—hematologic cancer	2.55e-05	0.00026	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—hematologic cancer	2.55e-05	0.00026	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD86—hematologic cancer	2.49e-05	0.000254	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFB—hematologic cancer	2.49e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—JAK2—hematologic cancer	2.48e-05	0.000252	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UGT1A1—hematologic cancer	2.46e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HES1—hematologic cancer	2.46e-05	0.00025	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NCOR1—hematologic cancer	2.45e-05	0.000249	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TSC2—hematologic cancer	2.43e-05	0.000248	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CSF2—hematologic cancer	2.42e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF1—hematologic cancer	2.42e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CRABP1—hematologic cancer	2.39e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC22A1—hematologic cancer	2.39e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FOXO1—hematologic cancer	2.38e-05	0.000243	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—hematologic cancer	2.38e-05	0.000242	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFRB—hematologic cancer	2.38e-05	0.000242	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—hematologic cancer	2.36e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFRA—hematologic cancer	2.34e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGFR3—hematologic cancer	2.34e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAK1—hematologic cancer	2.33e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCG—hematologic cancer	2.33e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALOX5—hematologic cancer	2.33e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK14—hematologic cancer	2.32e-05	0.000236	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—hematologic cancer	2.27e-05	0.000231	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NUP98—hematologic cancer	2.26e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FN1—hematologic cancer	2.25e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BAD—hematologic cancer	2.22e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKBIA—hematologic cancer	2.22e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH1—hematologic cancer	2.2e-05	0.000224	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADCY7—hematologic cancer	2.19e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA3—hematologic cancer	2.19e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2RA—hematologic cancer	2.18e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NUP214—hematologic cancer	2.18e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—hematologic cancer	2.16e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—hematologic cancer	2.16e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD80—hematologic cancer	2.15e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—hematologic cancer	2.15e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KIT—hematologic cancer	2.15e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—NRAS—hematologic cancer	2.15e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTR—hematologic cancer	2.13e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG2—hematologic cancer	2.13e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTPN11—hematologic cancer	2.11e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFB—hematologic cancer	2.1e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ENO2—hematologic cancer	2.09e-05	0.000213	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK3—hematologic cancer	2.06e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TSC2—hematologic cancer	2.06e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CREB1—hematologic cancer	2.05e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—hematologic cancer	2.03e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BRAF—hematologic cancer	2.02e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—hematologic cancer	2e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6R—hematologic cancer	1.99e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CREBBP—hematologic cancer	1.99e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SDC1—hematologic cancer	1.98e-05	0.000202	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR3—hematologic cancer	1.98e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK14—hematologic cancer	1.96e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—hematologic cancer	1.92e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAP2K1—hematologic cancer	1.9e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FN1—hematologic cancer	1.9e-05	0.000193	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—hematologic cancer	1.89e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BAD—hematologic cancer	1.87e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKBIA—hematologic cancer	1.87e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.87e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH1—hematologic cancer	1.86e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—hematologic cancer	1.85e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD80—hematologic cancer	1.82e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KIT—hematologic cancer	1.82e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—hematologic cancer	1.82e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NRAS—hematologic cancer	1.82e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF2—hematologic cancer	1.81e-05	0.000184	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTPN11—hematologic cancer	1.78e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3R1—hematologic cancer	1.78e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK3—hematologic cancer	1.74e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAK2—hematologic cancer	1.73e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CREB1—hematologic cancer	1.73e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BRAF—hematologic cancer	1.71e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—hematologic cancer	1.7e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDM2—hematologic cancer	1.69e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—hematologic cancer	1.69e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD44—hematologic cancer	1.69e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NQO1—hematologic cancer	1.69e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6R—hematologic cancer	1.69e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CREBBP—hematologic cancer	1.68e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MTOR—hematologic cancer	1.65e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—hematologic cancer	1.65e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAP2K1—hematologic cancer	1.61e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—hematologic cancer	1.6e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYCS—hematologic cancer	1.6e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.59e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.58e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HRAS—hematologic cancer	1.57e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—hematologic cancer	1.56e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1B—hematologic cancer	1.54e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF2—hematologic cancer	1.53e-05	0.000156	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—hematologic cancer	1.53e-05	0.000156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—hematologic cancer	1.51e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—hematologic cancer	1.51e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3R1—hematologic cancer	1.51e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—hematologic cancer	1.5e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—hematologic cancer	1.47e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUN—hematologic cancer	1.47e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAK2—hematologic cancer	1.46e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—hematologic cancer	1.44e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDM2—hematologic cancer	1.43e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1A—hematologic cancer	1.43e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—hematologic cancer	1.42e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.41e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK8—hematologic cancer	1.39e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—hematologic cancer	1.39e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTOR—hematologic cancer	1.39e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—hematologic cancer	1.39e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EP300—hematologic cancer	1.36e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.33e-05	0.000136	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HRAS—hematologic cancer	1.33e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—hematologic cancer	1.32e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1B—hematologic cancer	1.31e-05	0.000133	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.29e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.29e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—hematologic cancer	1.29e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—hematologic cancer	1.28e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—hematologic cancer	1.28e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—hematologic cancer	1.28e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—hematologic cancer	1.27e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—hematologic cancer	1.27e-05	0.000129	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRAS—hematologic cancer	1.27e-05	0.000129	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—hematologic cancer	1.25e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUN—hematologic cancer	1.24e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK3—hematologic cancer	1.22e-05	0.000124	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.21e-05	0.000123	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—hematologic cancer	1.2e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—hematologic cancer	1.18e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—hematologic cancer	1.18e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK8—hematologic cancer	1.18e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—hematologic cancer	1.17e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EP300—hematologic cancer	1.15e-05	0.000117	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.14e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—hematologic cancer	1.11e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—hematologic cancer	1.09e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—hematologic cancer	1.09e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—hematologic cancer	1.08e-05	0.000109	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRAS—hematologic cancer	1.07e-05	0.000109	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	1.03e-05	0.000105	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	1e-05	0.000102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—hematologic cancer	9.99e-06	0.000102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	9.97e-06	0.000101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—hematologic cancer	9.71e-06	9.88e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—hematologic cancer	9.6e-06	9.77e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HRAS—hematologic cancer	9.29e-06	9.45e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—hematologic cancer	9.23e-06	9.4e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CREBBP—hematologic cancer	8.9e-06	9.06e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—hematologic cancer	8.89e-06	9.05e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	8.48e-06	8.63e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—hematologic cancer	8.44e-06	8.59e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—hematologic cancer	8.33e-06	8.48e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—hematologic cancer	8.21e-06	8.35e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—hematologic cancer	8.2e-06	8.35e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3R1—hematologic cancer	7.97e-06	8.11e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRAS—hematologic cancer	7.85e-06	7.99e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—hematologic cancer	7.51e-06	7.65e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.36e-06	7.49e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—hematologic cancer	6.93e-06	7.05e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—hematologic cancer	6.36e-06	6.47e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—EP300—hematologic cancer	6.06e-06	6.17e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.48e-06	4.56e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—hematologic cancer	3.66e-06	3.73e-05	CbGpPWpGaD
